CIK 0001681087 · Non-accelerated filer<br>Smaller reporting company
Tectonic Therapeutic, Inc.
Sign in to watch- Ticker
- TECX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- NY
- Entity type
- operating
- EIN
- 810710585
- Phone
- (339) 666-3320
- Business address
- 490 ARSENAL WAY, SUITE 200, WATERTOWN, MA
- Former names
- AvroBio, Inc., AVROBIO, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,920
- in 2 filings, $14K under 10b5-1 plans
Net −$13,920. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 86 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-04 | Ruddy Marcella K. Chief Medical Officer | Grant or award · Employee Stock Option (Right to Buy) | +24,250 | 24,250 | ||
| 2026-03-04 | McNamara Peter Chief Scientific Officer | Grant or award 10b5-1 | +23,000 | 60,482 | ||
| 2026-03-04 | McNamara Peter Chief Scientific Officer | Sale 10b5-1 | −1,650 | $25.00 | $41K | 58,832 |
| 2026-03-04 | McNamara Peter Chief Scientific Officer | Grant or award · Employee Stock Option (Right to Buy) 10b5-1 | +21,000 | 21,000 | ||
| 2026-03-04 | Schwabish Marc Chief Business Officer | Grant or award | +19,500 | 45,314 | ||
| 2026-03-04 | Schwabish Marc Chief Business Officer | Grant or award · Employee Stock Option (Right to Buy) | +17,750 | 17,750 | ||
| 2026-03-04 | Lochner Daniel Chief Financial Officer | Grant or award | +26,500 | 58,544 | ||
| 2026-03-04 | Lochner Daniel Chief Financial Officer | Grant or award · Employee Stock Option (Right to Buy) | +24,250 | 24,250 | ||
| 2026-03-04 | REICIN ALISE Chief Executive Officer | Grant or award | +76,500 | 311,547 | ||
| 2026-03-04 | REICIN ALISE Chief Executive Officer | Grant or award · Employee Stock Option (Right to Buy) | +69,250 | 69,250 | ||
| 2026-03-03 | McNamara Peter Chief Scientific Officer | Sale 10b5-1 | −1,649 | $22.06 | $36K | 37,482 |
| 2026-02-11 | REICIN ALISE Chief Executive Officer | Purchase | +2,500 | $21.10 | $53K | 127,030 |
| 2026-02-11 | REICIN ALISE Chief Executive Officer | Purchase | +2,500 | $21.10 | $53K | 237,547 |
| 2026-02-10 | Schwabish Marc Chief Business Officer | Option exercise | +4,500 | $2.38 | $11K | 25,814 |
| 2026-02-10 | Schwabish Marc Chief Business Officer | Option exercise · Employee Stock Option (Right to Buy) | −4,500 | 82,014 | ||
| 2026-02-10 | Lochner Daniel Chief Financial Officer | Purchase | +6,000 | $21.61 | $130K | 32,044 |
| 2026-02-04 | Ruddy Marcella K. Chief Medical Officer | Shares withheld for taxes | −2,064 | $23.22 | $48K | 53,247 |
| 2026-02-04 | McNamara Peter Chief Scientific Officer | Shares withheld for taxes | −1,748 | $23.22 | $41K | 39,131 |
| 2026-02-04 | Schwabish Marc Chief Business Officer | Shares withheld for taxes | −1,619 | $23.22 | $38K | 21,314 |
| 2026-02-04 | Lochner Daniel Chief Financial Officer | Shares withheld for taxes | −2,077 | $23.22 | $48K | 26,044 |
Page 3 of 10 · 188 trades